Dimerix Ltd Company Profile

A phase 2 biotech with a scalable platform

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

  • Company
    Dimerix Ltd
  • Website
  • Sector
  • Industry
  • Code
  • Socials

Company Overview

Dimerix is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need.

Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment, DMX-200, that may transform the lives of patients with Kidney Disease. Dimerix has also recently developed other potential drugs in its pipeline, including DMX-700 for chronic obstructive pulmonary disease (COPD).

Share this profile:

A Stage 2 Biotech With A Growing Pipeline

Dimerix is using its Receptor-HIT technology platform to discover novel treatments for a wide array of diseases, including Diabetic Kidney Disease (DKD), Focal Segmental Glomerulosclerosis (FSGS) and Chronic Obstructive Pulmonary Disease (COPD).
Stage 2

The DMX-200 drug candidate for DKD had successful results for its Stage 2a trials in 2017, and clinical studies are now fully recruited for its Stage 2b trials.


The Receptor-HIT technology platform allows Dimerix to find many potential drug candidates, including the recent DMX-700 for COPD.


Experienced management, patents and market positioning are in place, which increase the likelihood of successful commercial outcomes.

DMX-200, Strong Phase 2a Results

DMX-200, having cleared phase 2a trials, has shown strong and statistically significant evidence that it can tackle renal damage and Chronic Kidney Disease (CKD). DMX-200 was shown to reduce Proteinuria levels by a further 35.6% in addition to the 24% reduction in proteinuria seen in patients taking Irbesartan (the standard kidney disease drug). The addressable market for DMX-200 is estimated to be ~US$1.1bn per annum.

DMX-200 Latest

Get the latest developments on DMX-200

Drug Pipeline

Using its Receptor-HIT technology, Dimerix are able to discover and develop many potential drug candidates, including the recent DMX-700. Trial data for DMX-200 is expected as soon as Q2 2020.

Commercialisation Strategy

Dimerix have the experience necessary to discover and commercialise drugs by using a holistic approach. Key to this commercialisation strategy is the company's patent position. DMX-200 has significant protections in place for the U.S. market which also has relatively high rates of Diabetic Kidney Disease.

Latest presentation

View DXB's most up to date presentation

DMX-700, expanding the pipeline

COPD is a progressive and life-threatening lung disease and it is the fourth-leading cause of death in the world. Although treatments do exist, there is currently no way to slow progression of the condition or cure it. Dimerix have discovered that simultaneous inhibition of two particular receptors may significantly improve treatment efficacy (DMX-700). A provisional patent application over this has been lodged in order to secure what could be a significant discovery.

Experienced and Cohesive Team

The Dimerix team have a highly complimentary skill set and a track record of successfully commercialising biopharmaceutical products on the international stage with large global counter-parties such as Eli Lilly.

Clock icon Information current at 18 October 2019

News Coverage

Current news mentioning Dimerix Ltd from top publishers around the web.
Powered by  

Key Announcements

Management comments and explanations on key company announcements.
Need a full list of every announcement? Visit ASX

How do I invest?

Considering investing in Dimerix Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:DXB

    On your online investment platform search for the stock ticker code ASX:DXB to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.